Biomarker testing for people with advanced lung cancer in England
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Author
Adizie, Jana BTweedie, Judith
Khakwani, Aamir
Peach, Emily
Hubbard, Richard
Wood, Natasha
Gosney, John R
Harden, Susan V
Beckett, Paul
Popat, Sanjay
Navani, Neal
Affiliation
University Hospitals Birmingham NHS Foundation Trust; Belfast Health and Social Care Trust; University of Nottingham; Nottingham University Hospitals NHS Trust; Public Health England; Royal Liverpool University Hospital; Monash University; University Hospitals of Derby and Burton NHS Foundation Trust; Royal Marsden NHS Foundation Trust; University College LondonPublication date
2021-04-27
Metadata
Show full item recordAbstract
Introduction: Optimal management of people with advanced NSCLC depends on accurate identification of predictive markers. Yet, real-world data in this setting are limited. We describe the impact, timeliness, and outcomes of molecular testing for patients with advanced NSCLC and good performance status in England. Methods: In collaboration with Public Health England, patients with stages IIIB to IV NSCLC, with an Eastern Cooperative Oncology Group performance status of 0 to 2, in England, between June 2017 and December 2017, were identified. All English hospitals were invited to record information. Results: A total of 60 of 142 invited hospitals in England participated in this study and submitted data on 1157 patients. During the study period, 83% of patients with advanced adenocarcinoma underwent molecular testing for three recommended predictive biomarkers (EGFR, ALK, and programmed death-ligand 1). A total of 80% of patients with nonsquamous carcinomas on whom biomarker testing was performed had adequate tissue for analysis on initial sampling. First-line treatment with a tyrosine kinase inhibitor was received by 71% of patients with adenocarcinoma and a sensitizing EGFR mutation and by 59% of those with an ALK translocation. Of patients with no driver mutation and a programmed death-ligand 1 expression of greater than or equal to 50%, 47% received immunotherapy. Conclusions: We present a comprehensive data set for molecular testing in England. Although molecular testing is well established in England, timeliness and uptake of targeted therapies should be improved.Citation
Adizie JB, Tweedie J, Khakwani A, Peach E, Hubbard R, Wood N, Gosney JR, Harden SV, Beckett P, Popat S, Navani N. Biomarker Testing for People With Advanced Lung Cancer in England. JTO Clin Res Rep. 2021 Apr 27;2(6):100176. doi: 10.1016/j.jtocrr.2021.100176.Type
ArticleAdditional Links
https://www.jtocrr.org/PMID
34590024Publisher
Elsevierae974a485f413a2113503eed53cd6c53
10.1016/j.jtocrr.2021.100176